Life Sciences Company Presentation Template

Life sciences presentations operate under a distinct set of constraints. Regulatory requirements govern what clinical claims can be made and how data must be characterized. Investor expectations for the biotech, medtech, and diagnostics sectors differ meaningfully from those for software or services companies. Partnering discussions require protecting proprietary data while conveying enough scientific credibility to motivate a deal. And clinical milestone updates must communicate complex trial data to audiences that range from highly technical scientific advisory boards to generalist institutional investors.

This template covers the four core presentation types for life sciences companies: the investor pitch, the partnering conference deck, the clinical milestone update, and the regulatory strategy briefing.

Investor Pitch Presentation

The life sciences investor pitch balances scientific credibility with investment narrative. Investors must believe the science is real, the team can execute, and the return profile justifies the binary clinical risk.

Slide 1: The Problem Define the disease area and the unmet medical need with specificity. How many patients? What is the current standard of care? What does it fail to address? Use epidemiology data and describe patient burden in clinical terms — not commercial terms at this stage.

Slide 2: The Solution Describe your therapeutic, diagnostic, or device approach in two to three sentences at a level a non-specialist can follow. What is the mechanism? What differentiates your approach from existing treatments or competitive programs?

Slide 3: Pipeline Overview Present your full pipeline using the standard stage-gate chart: Discovery, Preclinical, Phase 1, Phase 2, Phase 3, Approval. Color-code by therapeutic area or program type. Include partnered programs separately from wholly-owned ones.

Slide 4: Lead Program — Scientific Rationale Go deeper on the lead program. What is the target? What is the evidence of target validation? What is the proposed mechanism of action and the hypothesized path from biological effect to clinical benefit? Include the most important preclinical data: efficacy data in the most predictive model, safety and tolerability summary, and any biomarker data that supports clinical translatability.

Slide 5: Clinical Data If you have clinical data, present it with appropriate statistical context. Efficacy endpoints, confidence intervals, p-values, patient numbers. Do not extrapolate from Phase 1 safety data to efficacy claims. Characterize what has been shown and what remains to be shown. Be precise about the patient population studied.

Slide 6: Clinical Development Plan Outline the path to approval: the next trial, the primary endpoint, the patient population, the planned enrollment, the timeline to data readout, and the regulatory pathway (IND, FDA Breakthrough designation if applicable, EMA precedent).

Slide 7: Market Opportunity Define the addressable patient population, the anticipated pricing based on clinical value and comparable therapies, and the peak revenue potential. Show the basis for the pricing assumption and the market penetration scenario used.

Slide 8: Competitive Landscape Map your program against competitors on the dimensions that matter most in your indication: mechanism, stage of development, efficacy data if available, safety profile, and route of administration. Be honest about where competitors have advantages.

Slide 9: Intellectual Property Summarize the IP estate: composition of matter patents, method of use patents, key jurisdictions, expiry dates. For platform companies, describe the breadth and durability of the platform IP.

Slide 10: Team Present the leadership team with relevant prior experience: clinical development expertise, regulatory track record (prior NDA/BLA approvals), commercial experience, and scientific advisory board composition.

Slide 11: Financing and Use of Proceeds State the round size, the use of proceeds by category (clinical trial execution, manufacturing, general corporate), and the key milestones the financing is designed to fund. Include the inflection points that will drive value before the next financing event.

Partnering Conference Deck

The partnering conference deck — used at JPMorgan, BIO International, ASCO, ASH, or bilateral in-licensing discussions — is a more compressed version of the investor pitch, optimized for a 20-minute one-on-one with a business development counterpart.

Slide 1: Company Snapshot One slide: mission, lead program in one sentence, clinical stage, and key data readout timeline.

Slide 2: Unmet Need and Program Rationale Tight summary of the unmet need and why your approach is differentiated. Two to three slides maximum.

Slide 3: Key Data Lead with the most compelling data you have. If you have Phase 2 data, present the headline result with appropriate statistical context. If you are pre-data, present the strongest preclinical evidence and explain why it is predictive.

Slide 4: Development Plan and Timeline The specific next steps, milestones, and data readouts the partner will be investing in or co-developing with you. Be specific about what a partnership would fund and what the partner would receive.

Slide 5: Partnership Opportunity Clearly define what you are seeking: co-development, co-commercialization, regional licensing, global rights ex-US, or full acquisition. State what you are willing to offer and what you intend to retain.

Slide 6: Contact and Next Steps Name, email, and the specific follow-up you are requesting: a data package request, a term sheet conversation, or a site visit.

Clinical Milestone Update

The clinical milestone update communicates trial progress and data readouts to investors, board members, and scientific advisors. The audience may range from highly technical to generalist, so the deck must work at multiple levels simultaneously.

Slide 1: Trial Summary State the trial name, phase, indication, primary endpoint, enrollment status (current versus target), and the expected readout timeline. One slide, complete picture.

Slide 2: Enrollment and Site Activation If enrollment is ongoing, show the ramp curve: cumulative patients enrolled by month against the planned curve. Site activation by geography. Any protocol amendments that affected enrollment.

Slide 3: Data Readout — Results Present the primary endpoint results with full statistical context: the effect size, confidence interval, p-value, and the pre-specified significance threshold. Describe the patient population analyzed. Present secondary endpoints with the same rigor. If the trial missed its primary endpoint, present the result honestly and provide management's interpretation.

Slide 4: Safety Summary Present the safety and tolerability profile: treatment-emergent adverse events by system organ class, serious adverse events, discontinuations due to adverse events, and deaths. Compare to the control arm where applicable.

Slide 5: Subgroup Analysis Present pre-specified subgroup analyses that may inform the regulatory path or the next clinical strategy. Be explicit that subgroup analyses are exploratory unless they were pre-specified.

Slide 6: Next Steps Define the regulatory strategy, the next trial, or the business development milestones that follow from the data readout. What does management intend to do, and on what timeline?

Regulatory Strategy Briefing

The regulatory strategy briefing is presented to the board, scientific advisory board, or investors to explain the regulatory pathway, the FDA interaction history, and the risk factors in the approval path.

Slide 1: Regulatory Pathway Summary Define the regulatory pathway: standard approval, Breakthrough Therapy designation, Accelerated Approval, Fast Track, Priority Review, or Orphan Drug designation. Explain what each designation means for the timeline and the evidentiary standard.

Slide 2: FDA Meeting History Summarize the key FDA interactions to date: Type A, B, and C meetings, the key questions asked, and FDA's responses. Describe any areas of agreement and any areas where alignment is still pending.

Slide 3: NDA/BLA Filing Plan Present the anticipated submission timeline, the planned data package, and the regulatory review timeline. Flag any manufacturing or CMC issues that could affect the submission.

Slide 4: Risk Assessment Identify the key regulatory risks: clinical data sufficiency, safety signals that may generate an advisory committee meeting, manufacturing readiness, and label negotiation. For each risk, describe the probability and the mitigation strategy.

---

Common Life Sciences Presentation Mistakes

Overstating what data shows. Describe exactly what was measured, in what population, with what degree of certainty. The FDA and sophisticated investors will hold you to your characterizations.

Burying the data in methods. Lead with the result, then provide the context. Don't make a scientific audience read through three slides of methodology before seeing the headline number.

Ignoring competitive programs. If there are three other programs in the same indication, acknowledge them and explain why yours is differentiated.

---

Build Your Life Sciences Presentations

slide-deck.io generates life sciences investor pitches, partnering decks, clinical milestone updates, and regulatory strategy briefings — with pipeline waterfall charts, clinical data summary slides, and milestone timeline visualizations.

Create your life sciences presentation